Literature DB >> 25765690

[Abnormal expression of chemokine receptor on B cells in patients with SLE].

Maiko Yoshikawa1, Shingo Nakayamada, Shigeru Iwata, Satoshi Kubo, Naoki Yunoue, Sheau-Pey Wang, Yoshiya Tanaka.   

Abstract

SLE is a systemic autoimmune disease characterized by overactivation of autoreactive memory B cells. However, little is known about the mechanism of qualitative abnormality of B cells. The subset classification of T cells by expression pattern of master transcription factors and chemokine receptors has been established. The biology of T cells is useful information to assess qualitative abnormality of B cells. Therefore, we focused on the expression of chemokine receptors such as CXCR5 and CXCR3 on B cells in order to define the B cell subset classification in patients with SLE. Our results revealed that pathological B cells, which lose CXCR5 and express CXCR3, might be involved in autoantibody production through the interaction with Tfh cells, and in acquisition of effector function of memory B cells during the pathological process in SLE. In addition, the results revealed that those effector B cells still remained after improvement of disease activity by immunosuppressive therapy, indicating that the quantitative abnormality, which is not improved by current therapy, may underlie in this disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25765690     DOI: 10.2177/jsci.38.65

Source DB:  PubMed          Journal:  Nihon Rinsho Meneki Gakkai Kaishi        ISSN: 0911-4300


  1 in total

1.  CD11c+ T-bet+ CD21hi B Cells Are Negatively Associated With Renal Impairment in Systemic Lupus Erythematosus and Act as a Marker for Nephritis Remission.

Authors:  Víctor A Sosa-Hernández; Sandra Romero-Ramírez; Rodrigo Cervantes-Díaz; Daniel A Carrillo-Vázquez; Itze C Navarro-Hernandez; Laura P Whittall-García; Abdiel Absalón-Aguilar; Ana S Vargas-Castro; Raúl F Reyes-Huerta; Guillermo Juárez-Vega; David E Meza-Sánchez; Vianney Ortiz-Navarrete; Jiram Torres-Ruiz; Nancy R Mejía-Domínguez; Diana Gómez-Martín; José L Maravillas-Montero
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.